Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.

× No keyword cloud information.

10 in total

1. Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale.

Authors: Tyler A Davis; Anna E Vilgelm; Ann Richmond; Jeffrey N Johnston
Journal: J Org Chem Date: 2013-10-15 Impact factor: 4.354

2. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.

Authors: Matthew J J Rose-Zerilli; Jade Forster; Helen Parker; Anton Parker; Ana E Rodríguez; Tracy Chaplin; Anne Gardiner; Andrew J Steele; Andrew Collins; Bryan D Young; Anna Skowronska; Daniel Catovsky; Tatjana Stankovic; David G Oscier; Jonathan C Strefford
Journal: Haematologica Date: 2014-02-28 Impact factor: 9.941

3. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.

Authors: Veronika Navrkalova; Ludmila Sebejova; Jana Zemanova; Jana Kminkova; Blanka Kubesova; Jitka Malcikova; Marek Mraz; Jana Smardova; Sarka Pavlova; Michael Doubek; Yvona Brychtova; David Potesil; Veronika Nemethova; Jiri Mayer; Sarka Pospisilova; Martin Trbusek
Journal: Haematologica Date: 2013-04-12 Impact factor: 9.941

4. IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.

Authors: Yandong Shen; Kyle Crassini; Narjis Fatima; Michael O'Dwyer; Michael O'Neill; Richard I Christopherson; Stephen P Mulligan; O Giles Best
Journal: Blood Adv Date: 2020-10-27

5. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.

Authors: Ellen J Schlette; Joan Admirand; William Wierda; Lynne Abruzzo; Katherine I Lin; Susan O'Brien; Susan Lerner; Michael J Keating; Constantine Tam
Journal: Leuk Lymphoma Date: 2009-10

6. Functional assessment of p53 in chronic lymphocytic leukemia.

Authors: M Le Garff-Tavernier; H Blons; F Nguyen-Khac; M Pannetier; M Brissard; S Gueguen; F Jacob; L Ysebaert; S A Susin; H Merle-Béral
Journal: Blood Cancer J Date: 2011-02-25 Impact factor: 11.037

7. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).

Authors: Y Jiang; H-C Chen; X Su; P A Thompson; X Liu; K-A Do; W Wierda; M J Keating; W Plunkett
Journal: Blood Cancer J Date: 2016-09-02 Impact factor: 11.037

8. Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation.

Authors: Yvonne Kiefer; Christoph Schulte; Markus Tiemann; Joern Bullerdiek
Journal: Appl Clin Genet Date: 2012-03-12

9. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.

Authors: G D te Raa; P D Moerland; A C Leeksma; I A Derks; H Yigittop; N Laddach; M Loden-van Straaten; V Navrkalova; M Trbusek; D M Luijks; T Zenz; A Skowronska; M Hoogendoorn; T Stankovic; M H van Oers; E Eldering; A P Kater
Journal: Cell Death Dis Date: 2015-08-06 Impact factor: 8.469

10. Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.

Authors: Federico Pozzo; Michele Dal Bo; Nadia Peragine; Riccardo Bomben; Antonella Zucchetto; Francesca Rossi; Massimo Degan; Davide Rossi; Annalisa Chiarenza; Alberto Grossi; Francesco Di Raimondo; Francesco Zaja; Gabriele Pozzato; Paola Secchiero; Gianluca Gaidano; Giovanni Del Poeta; Giorgio Zauli; Robin Fo À; Anna Guarini; Valter Gattei
Journal: J Hematol Oncol Date: 2013-11-05 Impact factor: 17.388

10 in total